PMID: 12145243
Question: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 12145243
Question: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content:** The question seeks to determine if lower fasting plasma glucose (FPG) levels at the time of type 2 diabetes diagnosis correlate with improved clinical outcomes.
- **Key Information to Look For:** Evidence linking lower initial FPG levels with reduced incidence of diabetic complications or other adverse outcomes in individuals diagnosed with type 2 diabetes.

**2. Evidence Evaluation**
- **Research Results:** The study analyzed 5,088 participants and categorized them based on their FPG levels at diagnosis into low, intermediate, and high groups. Findings indicate that individuals in the low FPG group had fewer complications such as retinopathy, abnormal biothesiometer measurements, and erectile dysfunction. Additionally, this group showed a reduced risk for most predefined clinical outcomes except stroke.
- **Strength and Reliability:** The study is large-scale, involving over 5,000 participants, which enhances the reliability of the findings. It also appears to have a prospective design, which is appropriate for assessing outcomes over time.
- **Relevance to the Question:** The evidence directly addresses the association between initial FPG levels and subsequent clinical outcomes, providing relevant and supportive data to answer the question.

**3. Conclusion**
Based on the study's findings, lower FPG levels at the diagnosis of type 2 diabetes are associated with fewer adverse clinical outcomes. This suggests that early detection and achieving lower glycemic levels at diagnosis can lead to improved patient outcomes.

**4. Final Answer**
**My final choice is: "yes"**
GPT selected: yes

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether lower fasting plasma glucose (FPG) levels at diagnosis of type 2 diabetes correlate with improved clinical outcomes. Key elements to evaluate include:  
- Comparison of outcomes across FPG categories (low, intermediate, high).  
- Whether lower FPG at diagnosis is associated with fewer complications (e.g., retinopathy, cardiovascular events) or slower disease progression.  

**2. Evidence Evaluation**  
The abstract states:  
- **Baseline Findings**: Patients with low FPG (<140 mg/dl) had fewer retinopathy, sensory abnormalities, and erectile dysfunction at diagnosis.  
- **Long-term Outcomes**: The low and intermediate FPG groups had reduced risks for most clinical outcomes (e.g., progression of retinopathy, microalbuminuria) compared to the high FPG group.  
- **Glycemic Progression**: All groups showed similar rates of FPG and HbA1c increase over time, but absolute differences in outcomes persisted.  
- **Relevance**: The study directly addresses the question by comparing outcomes based on FPG at diagnosis and highlights that lower initial glycemia correlates with better outcomes, even with similar disease progression rates.  

**3. Conclusion**  
The evidence strongly supports that lower FPG at diagnosis is associated with improved outcomes. The study demonstrates that patients with lower FPG at diagnosis had fewer complications at baseline and reduced risks for progression of microvascular and macrovascular outcomes. The consistency across multiple endpoints and the large sample size (5,088 participants) strengthen the reliability of these findings.  

**4. Final Answer:**  
**My final choice is: "yes"**
Qwen selected: yes

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether lower fasting plasma glucose (FPG) levels at type 2 diabetes diagnosis correlate with improved outcomes. Key information to evaluate includes:  
- Comparisons of clinical outcomes (e.g., retinopathy, neuropathy, cardiovascular events) across FPG categories.  
- Evidence linking lower initial FPG to reduced risk of complications or disease progression.  

**2. Evidence Evaluation**  
The study compared outcomes in three FPG groups:  
- **Low FPG (<7.8 mmol/l)**: Fewer complications (retinopathy, neuropathy, erectile dysfunction), reduced risk for most clinical outcomes (except stroke), and slower progression of microvascular complications.  
- **Intermediate FPG (7.8–10.0 mmol/l)**: Reduced risk for some outcomes (but not stroke or myocardial infarction).  
- **High FPG (≥10 mmol/l)**: Worse outcomes overall.  

Notably, absolute differences in glycemic measures persisted despite similar rates of FPG/HbA1c progression across groups. The authors conclude that lower initial glycemia predicts fewer adverse outcomes, likely due to earlier disease-stage detection.  

**3. Conclusion**  
The study provides robust evidence that lower FPG at diagnosis is associated with reduced complications and improved clinical outcomes, even with comparable glycemic progression rates. The findings directly support a "yes" answer.  

**4. Final Answer**  
**My final choice is: yes**
DeepSeek selected: yes

Initial consensus: All models selected yes

